Vaccine Strategic Analysis & Growth Outlook 2033

Vaccine by Type (Traditional Vaccines, o Live Attenuated, ▪ MMR, ▪ Varicella, o Inactivated, ▪ IPV, ▪ Influenza, o Toxoid, • Subunit & Conjugate, o Protein Subunit, ▪ Hep B, ▪ HPV, o Conjugate, ▪ Pneumococcal, ▪ Hib, • Genetic / Advanced, o mRNA, o Viral Vector, • Combination Vaccines), by Disease Indication (• Hepatitis, • Influenza, • MMR, • Cancer, • Rotavirus, • Herpes Zoster, • Covid-19, • Bacterial Diseases, • Others), by Route of Administration (• Oral, • Intramuscular, • Subcutaneous, • Intravenous), by Age Group (• Infants (0–12 months), • Children (1–9 years), • Adolescents (10–19 years), • Adults (20–59 years), • Elderly (≥60 years)), by Distribution Channel (• Hospitals, • Retail Pharmacies, • Government Suppliers, • Others), by Middle East & Africa, by Europe, by South America, by North America Forecast 2025-2033